When was Novalis Biotech founded?

Novalis Biotech was founded in 2018.

Where is Novalis Biotech's headquarters located?

Novalis Biotech's headquarters is located in Ghent (Belgium).

How big is Novalis Biotech's investment team?

Novalis Biotech has a team of 9, including 3 partners.

How many companies has Novalis Biotech invested in?

Novalis Biotech has invested in 18 companies, including Altavo & C-mo.

Which companies has Novalis Biotech invested in lately?

Altavo & Rarity Bioscience are the latest investments by Novalis Biotech.

How many exits has Novalis Biotech been involved in?

Novalis Biotech's portfolio has seen 2 acquisitions.

N8 Uwin Sports Betting India – Live Matches & Big Bonuses

Novalis Biotech, an accelerator and incubator program founded in 2018, is based in Ghent, Belgium. With a presence in 8 countries, it has supported around 18 startups in sectors like HealthTech, Life Sciences. As of Jan 2026, Novalis Biotech has witnessed 2 portfolio exits. Most notable companies in its portfolio include Altavo, C-mo and AlitheaGenomics. The program is backed by a team of 9 people who primarily support Series A startups based in Belgium. Its latest investment was a $3.51M Series A round in Altavo on Jan 23, 2026, which also saw participation from Beteiligungsmanagement Thuringen and CFH Management.

Key Metrics

Founded Year

2018

Location

Ghent, Belgium

Portfolio Companies

Altavo, C-mo & 16 more

Sectors of Investment

HealthTech, Life Sciences & 3 more

Stages of Investment

Seed & Series A

Locations of Investment

Belgium, Netherlands & 6 more

View Novalis Biotech's full profile

Novalis Biotech has a portfolio of 18 companies. Their most notable investments are in AlitheaGenomics and AlitheaGenomics.Their portfolio spans across Belgium, Netherlands, France and 5 more locations. They have invested in HealthTech, Life Sciences, High Tech and 2 other sectors, across stages such as Seed, Series A stages. Here is the list of top investments by Novalis Biotech:

1. Altavo

AI-based sounding voice for disabled individuals. The company has developed a natural-sounding voice that helps voiceless people sound using speech technology.

Key facts about Altavo

Location: Dresden (Germany)
Stage: Series A
Total Funding till date: $8.9M
Investors: OCCIDENT, HTGF and 16 Others
Latest Funding Round: Series A, Jan 23, 2026, $*****

2. C-mo

Provider of a cough monitoring and diagnostic device for healthcare providers. The company has developed a wearable smart device C-mo which has the ability to record cough patterns of an individual on a real time basis for further analysis. The device can be worn by patients or individuals to monitor cough patterns on a regular basis the recording of these can be analyzed on the C-mo’s software by doctors for disease diagnosis.

Key facts about C-mo

Founded Year: 2020
Location: Costa da Caparica (Portugal)
Stage: Seed
Total Funding till date: $4.81M
Employee Count: 4 as on Jul 01, 2024
Investors: Boehringer Ingelheim Venture Fund, HTGF and 3 Others
Latest Funding Round: Seed, Sep 01, 2022, $*****
Highlight: Editors' Pick

3. AlitheaGenomics

Provider of transcriptomics solutions for research and biomarker discovery. The company offers proprietary technology for RNA-seq of multiplex RNA samples for sequencing. The company also offers mRNA sequencing services and a kit that can be used for multiple samples.

Key facts about AlitheaGenomics

Founded Year: 2020
Location: Lausanne (Switzerland)
Stage: Seed
Total Funding till date: $4.23M
Employee Count: 9 as on Jul 01, 2024
Investors: TechU, FIT and 3 Others
Latest Funding Round: Seed, Mar 14, 2024, $*****
Highlight: Editors' Pick

4. Enzyre

Developer of smart diagnostics devices for blood coagulation analysis. It has developed the ENZYPAD devices that enable patient's blood coagulation analysis, with the measured data. It is a painless and easy to use blood sampling device that provides a test-specific single-use microfluidic cartridge includes all necessary reagents and controls. It uses proprietary innovative latent luciferin-protected peptide substrates to determine the activity of specific enzymes in the coagulation cascade. T

Key facts about Enzyre

Founded Year: 2016
Location: Nijmegen (Netherlands)
Stage: Series A
Total Funding till date: $11.9M
Employee Count: 18 as on Jul 01, 2024
Investors: Takeda Ventures, Oost NL and 3 Others
Latest Funding Round: Series A, Nov 02, 2022, $*****
Highlight: Editors' Pick

5. RheaVita

Developer of an instrument for continuous freeze-drying. The RheaVita Continuous Freeze-Drying Technology is used to integrate all freeze-drying process step unit operations in a continuous production line. The product provides constant infeed of unit doses and the concomitant removal of the dried product.

Key facts about RheaVita

Founded Year: 2018
Location: Ghent (Belgium)
Stage: Series A
Total Funding till date: $3.06M
Employee Count: 4 as on Dec 31, 2022
Investors: JLABS, PMV and 1 Other
Latest Funding Round: Series A, Jun 02, 2021, $*****
Highlight: Editors' Pick

View the full list of portfolio companies

Novalis Biotech has invested in 18 companies over the last 6 years, with an average of 2 new investments annually in the last 5 years. As of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Altavo and most recent follow-on round was in Altavo.

Here are Novalis Biotech's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	1	1
2025	0	0	0
2024	1	2	3
2023	1	0	1
2022	3	1	4
2021	3	0	3
2020	1	0	1

View all investments by Novalis Biotech

Novalis Biotech has made 5 investments in Seed stage with an average round size of $2.13M and 4 investments in Series A stage with an average round size of $3.61M.

Here are Novalis Biotech's investments by stage:

Stage of entry	No. of Investments
Seed	5
Series A	4

Note: We have considered here, only first round of investments

View all investments by Novalis Biotech

Novalis Biotech has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Internet of Things - Industry Applications and Enterprise Applications. Notably, it has invested in 17 Tech companies, 16 Enterprise (B2B) companies, 6 Software companies and at least 6 companies focusing on Tech hardware.

Here are Novalis Biotech's investments by sector:

Sector	No. of Investments
Life Sciences	8
High Tech	5
HealthTech	3
Internet of Things - Industry Applications	2
Enterprise Applications	1

Note: We have considered here, only first round of investments

View all investments by Novalis Biotech

Novalis Biotech has made most investments in Belgium (2), followed by France where it has made 2 investments.

Here are Novalis Biotech's investments by geography:

Country	No. of Investments
Belgium	2
France	2
Germany	1
Netherlands	1
Portugal	1
Others	2

Note: We have considered here, only first round of investments

View all investments by Novalis Biotech

Novalis Biotech has made 1 investments in 2026 so far - Altavo.

Here are the most recent investments by Novalis Biotech:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Jan 23, 2026	Altavo	Germany	Series A	4086	Beteiligungsmanagement Thuringen [+3]
Jun 18, 2024	Rarity Bioscience	Sweden	Series A	4163	Navigare Ventures [+1]
Mar 14, 2024	AlitheaGenomics	Switzerland	Seed	2870	TechU
Feb 20, 2024	Altavo	Germany	Series A	7074	Beteiligungsmanagement Thuringen [+5]
Feb 06, 2023	Rarity Bioscience	Sweden	Seed	8480	-

See more recent investments made by Novalis Biotech

2 companies from Novalis Biotech's portfolio have been acquired. The most recent acquisition were Cergentis in Jul 2022 by Solvias.

Here are Novalis Biotech's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Cergentis	Jul 12, 2022	-	-	8475
doc.ai	Jan 28, 2021	-	-	8432

View all acquired companies in Novalis Biotech's portfolio

Novalis Biotech has a team of 9 members including 3 Partners and 1 Venture Partner located in Belgium and United Kingdom. Novalis Biotech's team does not sit on the board of any company as of now.

Here is a list of all team members in Novalis Biotech:

Name	Designation	Location	Board Memberships	Contact details
Wim Van Criekinge	Partner	Antwerp	-	1 Email
Jan Van Den Berghe	Partner	Cranbrook	-	1 Email
Bart Rossel	Partner	Ghent	-	1 Email
Cedric Bogaert	Venture Partner	Ghent	-	1 Email

View team details of Novalis Biotech

Over the past 6 years, 25 investors have co-invested in Novalis Biotech's portfolio companies. This includes funds and angels.

Invested before Novalis Biotech: EIT Health, CFH Management and 5 others have invested in rounds before Novalis Biotech. There are 2 companies where EIT Health has invested before Novalis Biotech and 1 company where CFH Management has invested before Novalis Biotech.
Top Co-investors of Novalis Biotech: 12 investors entered a company along with Novalis Biotech. These include investors like Bpifrance (2 companies).
Invested after Novalis Biotech: A total of 6 investors have invested in Novalis Biotech's portfolio after their investments. Top Investors include TechU (1 company) and Oost NL (1 company).